Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

PURPOSE: The SP142 PD-L1 assay is a companion diagnostic for atezolizumab in metastatic triple-negative breast cancer (TNBC). We strove to understand the biological, genomic, and clinical characteristics associated with SP142 PD-L1 positivity in TNBC patients. METHODS: Using 149 TNBC formalin-fixed...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Sung Gwe, Kim, Seon-Kyu, Shepherd, Jonathan H., Cha, Yoon Jin, Bae, Soong June, Kim, Chungyeul, Jeong, Joon, Perou, Charles M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233296/
https://www.ncbi.nlm.nih.gov/pubmed/33770313
http://dx.doi.org/10.1007/s10549-021-06193-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233296/
https://www.ncbi.nlm.nih.gov/pubmed/33770313
http://dx.doi.org/10.1007/s10549-021-06193-9

Ejemplares similares